Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 1;142(9):2845-2859.
doi: 10.1093/brain/awz205.

Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone

Affiliations

Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone

Jun Sung Lee et al. Brain. .

Abstract

Mutations in lysosomal genes increase the risk of neurodegenerative diseases, as is the case for Parkinson's disease. Here, we found that pathogenic and protective mutations in arylsulfatase A (ARSA), a gene responsible for metachromatic leukodystrophy, a lysosomal storage disorder, are linked to Parkinson's disease. Plasma ARSA protein levels were changed in Parkinson's disease patients. ARSA deficiency caused increases in α-synuclein aggregation and secretion, and increases in α-synuclein propagation in cells and nematodes. Despite being a lysosomal protein, ARSA directly interacts with α-synuclein in the cytosol. The interaction was more extensive with protective ARSA variant and less with pathogenic ARSA variant than wild-type. ARSA inhibited the in vitro fibrillation of α-synuclein in a dose-dependent manner. Ectopic expression of ARSA reversed the α-synuclein phenotypes in both cell and fly models of synucleinopathy, the effects correlating with the extent of the physical interaction between these molecules. Collectively, these results suggest that ARSA is a genetic modifier of Parkinson's disease pathogenesis, acting as a molecular chaperone for α-synuclein.

Keywords: Parkinson’s disease; arylsulfatase A; molecular chaperone; protein aggregation and propagation; α-synuclein.

PubMed Disclaimer

Comment in

  • ARSA variants in α-synucleinopathies.
    Makarious MB, Diez-Fairen M, Krohn L, Blauwendraat C, Bandres-Ciga S, Ding J, Pihlstrøm L, Houlden H, Scholz SW, Gan-Or Z. Makarious MB, et al. Brain. 2019 Dec 1;142(12):e70. doi: 10.1093/brain/awz340. Brain. 2019. PMID: 31670782 Free PMC article. No abstract available.
  • ARSA gene variants and Parkinson's disease.
    Fan Y, Mao CY, Dong YL, Shen S, Zhang QM, Yao DB, Liu F, Li MJ, Hu XC, Wang T, Liu YT, Liu H, Wang YL, Yuan YP, Zhang C, Yang J, Shi CH, Xu YM. Fan Y, et al. Brain. 2020 Jun 1;143(6):e47. doi: 10.1093/brain/awaa134. Brain. 2020. PMID: 32437521 No abstract available.
  • Reply: ARSA gene variants and Parkinson's disease.
    Lee SJ, Lee JS, Funayama M, Yoo HS, Lee PH, Hattori N. Lee SJ, et al. Brain. 2020 Jun 1;143(6):e48. doi: 10.1093/brain/awaa136. Brain. 2020. PMID: 32437537 No abstract available.

Publication types

MeSH terms

LinkOut - more resources